What is the translation of " HIPERTENZIJOM " in English?

• hypertension
• hypertensive

Examples of using Hipertenzijom in Croatian and their translations into English

Ne s njom i njenom hipertenzijom.
Not with her hypertension.

Hipertenzijom se smatra stanje kod kojega su vrijednosti krvnog tlaka trajno na razini od/iznad 140/90 mmHg.
High blood pressure is present if the resting blood pressure is persistently at or above 140/90 mmHg for most adults.

Primjena u bolesnika s hipertenzijom.
Use in patients with hypertension.

Najčešće se javlja osjećaj suhoće uz čestu uporabu lijekova namijenjenih borbi protiv manifestacija alergija, s neurastenijom, kao i hipertenzijom.
Most often, the feeling of dryness occurs with frequent use of drugs designed to combat allergy manifestations, with neurasthenia, as well as with hypertension.

Imate li problema s hipertenzijom?
Do you have problems with hypertension?

Potreban je oprez u bolesnika s hipertenzijom i teškim oštećenjem funkcije bubrega ili završnim stadijem bubrežne bolesti, jer nema iskustva s primjenom Edarbija u tih bolesnika vidjeti dio 4.4 i 5.2.
Caution should be exercised in hypertensive patients with severe renal impairment and end stage renal disease as there is no experience of use of Edarbi in these patients see sections 4.4 and 5.2.

Folk lijekovi za prehlade s hipertenzijom.
Folk remedies for colds with hypertension.

Tadalafil generik primjenjuje se u bolesnika s plućnom arterijskom hipertenzijom(PAH) stupnja II.(s blagim ograničenjem tjelesne aktivnosti) ili stupnja III.(sa značajnim ograničenjem tjelesne aktivnosti).
Tadalafil Generics is used in patients with class-II(slight limitation of physical activity) or class-III(marked limitation of physical activity) PAH.

Djelotvornost u odraslih bolesnika s plućnom hipertenzijom.
Efficacy in adult patients with pulmonary hypertension.

Bolesnicima koji već imaju očne poremećaje(npr. retinopatije povezane s dijabetesom ili hipertenzijom) preporučuju se periodički očni pregledi za vrijeme trajanja kombinirane terapije s alfa interferonima.
Patients with preexisting ophthalmologic disorders(e.g., diabetic or hypertensive retinopathy) should receive periodic ophthalmologic exams during combination therapy with alpha interferons.

Toliko je nemoguće liječiti hladno s hipertenzijom.
Than to treat a cold with hypertension categorically it is impossible.

Nakon kronične primjene doze od 80 mg tri puta na dan u bolesnika s plućnom arterijskom hipertenzijom opaženi su slabiji učinci na sniženje krvnog tlaka sniženje i sistoličkog i dijastoličkog tlaka za 2 mmHg.
After chronic dosing of 80 mg three times a day to patients with pulmonary arterial hypertension lesser effects in blood pressure reduction were observed a reduction in both systolic and diastolic pressure of 2 mm Hg.

Djelotvornost u bolesnika s plućnom arterijskom hipertenzijom PAH.
Efficacy in patients with pulmonary arterial hypertension PAH.

Nakon kronične primjene doze od 80 mg tri puta na dan u bolesnika sa sistemskom hipertenzijom, srednja vrijednost promjene u odnosu na početne vrijednosti činilo je sniženje sistoličkog i dijastoličkog krvnog tlaka za 9, 4 mmHg, odnosno, 9, 1 mmHg.
After chronic dosing of 80 mg three times a day to patients with systemic hypertension the mean change from baseline in systolic and diastolic blood pressure was a decrease of 9.4 mm Hg and 9.1 mm Hg respectively.

Uobičajeno je zadržavanje vode i natrija, te može rezultirati hipertenzijom.
Water and sodium retention is common and can lead to hypertension.

U dvije tromjesečne, kontrolirane kliničke studije u bolesnika s glaukomom otvorenog kuta ili hipertenzijom oka i prosječnim početnim IOT od 23 do 26 mmHg, prosječni učinak sniženja IOT DuoTrav kapi doziranih jednom dnevno ujutro bio je 7 do 9 mmHg.
In two three-month, controlled clinical studies in patients with open-angle glaucoma or ocular hypertension and baseline mean IOP of 23 to 26 mmHg, the mean IOP-lowering effect of DuoTrav dosed once-daily in the morning was 7 to 9 mmHg.

Općenito se pokazalo da je incidencija nuspojava(osobito“omaglica”) blago viša u bolesnika s hipertenzijom u anamanezi.
In general, the incidence of adverse reactions(especially“dizziness”) has been shown to be slightly higher in patients with a history of hypertension.

U dvanaestomjesečnoj, kontroliranoj kliničkoj studiji u bolesnika s glaukomom otvorenog kuta ili hipertenzijom oka i prosječnom početnom vrijednosti IOT od 25 do 27 mmHg, prosječni učinak sniženja IOT DuoTrav kapi doziranih jednom dnevno ujutro bio je 8 do 10 mmHg.
In a twelve-month, controlled clinical study in patients with open-angle glaucoma or ocular hypertension and baseline mean IOP of 25 to 27 mmHg, the mean IOP-lowering effect of DuoTrav dosed once-daily in the morning was 8 to 10 mmHg.

Ako je u analizi hormona hipofize detektiran višak ACGT-a, onda se može pojaviti Itenko-Cushingova bolest, praćena hipertenzijom, masnim naslagama i oštećenim imunitetom.
If an excess of ACGT was detected in the analysis of pituitary hormones, then Itenko-Cushing's disease may occur, accompanied by hypertension, fat deposits and impaired immunity.

Muškarca, starog 52 godine, s prethodno neliječenom hipertenzijom( vrijednosti tlaka do 230/ 140 mmHg) i dijabetesom, ali bez potvrđene bolesti srca i bez podataka o prethodnim ubodima himenoptera, ubo je stršljen u vrat dok je šetao šumom.
A 52 years-old man, with antecedent untreated hypertension( blood pressure values up to 230/ 140 mmHg) and diabetes, but without confirmed coronary disease and without data on previous hymenoptera stings, was stung in the neck by a hornet while walking in the forest.

Zbog činjenice da pretilost pogoršava položaj bolesnika s hipertenzijom, ovaj je rezultat posebno vrijedan.
Due to the fact that obesity exacerbates the position of hypertensive patients, this result is especially valuable.

Među 7 bolesnika s postojećom cirozom i/ili portalnom hipertenzijom koji su primali lumakaftor/ivakaftor u placebom kontroliranim ispitivanjima faze 3, u jednog bolesnika opaženo je pogoršanje funkcije jetre s povećanim ALT-om, AST-om, bilirubinom i hepatičkom encefalopatijom.
Among 7 patients with preexisting cirrhosis and/or portal hypertension who received lumacaftor/ivacaftor in the placebo-controlled, Phase 3 studies, worsening liver function with increased ALT, AST, bilirubin, and hepatic encephalopathy was observed in one patient.

Rasilamlo je ispitivan u većem broju aktivnih i placebom kontroliranih ispitivanja te dugotrajnih ispitivanja koja su uključivala ukupno 5570 hipertenzivnih bolesnika s blagom do umjerenom hipertenzijom dijastolički krvni tlak između 90 mmHg i 109 mmHg.
Rasilamlo was studied in a number of active and placebo-controlled trials and long-term trials which included a total of 5,570 hypertensive patients with mild to moderate hypertension diastolic blood pressure between 90 mmHg and 109 mmHg.

Tijekom kliničkih studija istodobne primjene bosentana i varfarina u bolesnika s plućnom arterijskom hipertenzijom nije došlo do klinički značajnih promjena internacionalnog normaliziranog omjera(INR) ili doze varfarina između početne i krajnje vrijednosti u kliničkim studijama.
Clinical experience with concomitant administration of bosentan with warfarin in patients with pulmonary arterial hypertension did not result in clinically relevant changes in International Normalized Ratio(INR) or warfarin dose baseline versus end of the clinical studies.

U kliničkom ispitivanju za utvrđivanje doze aksitiniba ispitanici koji su primali početne doze od 10 mg dvaput na dan ili 20 mg dvaput na dan iskusili su nuspojave koje uključuju hipertenziju, konvulzije povezane s hipertenzijom i smrtonosnu hemoptizu.
In a clinical dose finding study with axitinib, subjects who received starting doses of 10 mg twice daily or 20 mg twice daily experienced adverse reactions which included hypertension, seizures associated with hypertension, and fatal haemoptysis.

U unaprijed definiranim podskupinama, 57%(stariji bolesnici), 56%(bolesnici sa šećernom bolešću), 59%(bolesnici s dislipidemijom) i 60%(bolesnici s hipertenzijom u anamnezi) svih zabilježenih pokušaja uz vardenafil 10 mg raspadljive tablete za usta bilo je uspješno u smislu održavanja erekcije.
In the predefined subgroups 57%(elderly patients), 56%(patients with history of diabetes mellitus), 59%(patients with history of dyslipidemia) and 60%(patients with history of hypertension) of all reported attempts with vardenafil 10 mg orodispersible tablets were successful in terms of maintenance of erection.

U bolesnika s blagom do umjerenom hipertenzijom, 15-minutna infuzija fosaprepitanta u dozi od 100 mg s diltiazemom u dozi od 120 mg triput na dan dovela je do povećanja AUC diltiazema za 1, 4 puta te do malog, ali klinički značajnog pada krvnog tlaka, ali nije dovela do klinički značajne promjene u broju otkucaja srca odnosno PR-intervala.
In patients with mild to moderate hypertension, infusion of 100 mg of fosaprepitant over 15 minutes with diltiazem 120 mg 3 times daily, resulted in a 1.4-fold increase in diltiazem AUC and a small but clinically meaningful decrease in blood pressure, but did not result in a clinically meaningful change in heart rate, or PR interval.

Zbog nedostatka podataka, Zurampic se ne preporučuje u bolesnika s nestabilnom anginom, zatajenjem srca NYHA(New York Heart Association) stadija III ili IV, nekontroliranom hipertenzijom ili nedavnim infarktom miokarda, moždanim udarom ili dubokom venskom trombozom unutar posljednjih 12 mjeseci.
Zurampic is not recommended in patients with unstable angina, New York Heart Association(NYHA) class III or IV heart failure, uncontrolled hypertension or with a recent event of myocardial infarction, stroke, or deep venous thrombosis within the last 12 months, due to insufficient data.

U kliničkim ispitivanjima aliskiren nije ispitivan u hipertenzivnih bolesnika s teškim oštećenjem bubrežne funkcije( kreatinin u serumu ≥150 μmol/ l ili 1, 70 mg/ dl u žena, te ≥177 μmol/ l ili 2, 00 mg/ dl u muškaraca i/ ili procijenjena brzina glomerularne filtracije( GFR)< 30 ml/ min/ 1, 73 m2), dijalizom, nefrotskim sindromom ili renovaskularnom hipertenzijom u anamnezi.
In clinical studies aliskiren has not been investigated in hypertensive patients with severe renal impairment(serum creatinine≥150 μmol/l or 1.70 mg/dl in women and≥177 μmol/l or 2.00 mg/dl in men and/or estimated GFR< 30 ml/min/1.73 m2), history of dialysis, nephrotic syndrome or renovascular hypertension.

Kod diferenciranog karcinoma štitnjače bolesnici s hipertenzijom na početku liječenja imali su višu incidenciju 3. ili 4. stupnja hipertenzije, proteinurije, proljeva i dehidracije te su imali ozbiljnije slučajeve dehidracije, hipotenzije, plućne embolije, malignog pleuralnog izljeva, atrijske fibrilacije i gastrointestinalnih simptoma abdominalni bol, proljev, povraćanje.
In DTC, patients with baseline hypertension had a higher incidence of Grade 3 or 4 hypertension, proteinuria, diarrhoea, and dehydration, and experienced more serious cases of dehydration, hypotension, pulmonary embolism, malignant pleural effusion, atrial fibrillation, and GI symptoms abdominal pain, diarrhoea, vomiting.